Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
Valerie Theobald
Advertisement
Valerie Theobald is director, immunoanalytical services at Charles River Laboratories.
Articles by Valerie Theobald
Advertisement
Latest Updated Articles
Emerging Therapies Test Existing Bioanalytical MethodsApril 15th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
3
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
4
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
5